Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-21,300
Closed -$2.55M 5999
2021
Q4
$2.55M Hold
21,300
﹤0.01% 3123
2021
Q3
$2.63M Sell
21,300
-12,600
-37% -$1.62M ﹤0.01% 2763
2021
Q2
$4.07M Buy
33,900
+21,300
+169% +$2.43M ﹤0.01% 2229
2021
Q1
$1.32M Buy
+12,600
New +$1.28M ﹤0.01% 2895
2018
Q2
Sell
-3,000
Closed -$231K 3924
2018
Q1
$231K Buy
+3,000
New +$222K ﹤0.01% 3268
2014
Q3
Sell
-38,700
Closed -$1.51M 4419
2014
Q2
$1.51M Hold
38,700
﹤0.01% 2560
2014
Q1
$1.41M Buy
+38,700
New +$1.41M ﹤0.01% 2727

Other funds holding XYL

David Shaw's XYL Position: Q2 2026 in Review

David Shaw reduced its Xylem (XYL) stake by 6.5% in Q2 2026, selling an estimated $4.79M and leaving 600,585 shares worth $71M. The position accounts for 0.03% of the portfolio, ranked #587.

David Shaw first reported a position in XYL in Q2 2013 and has held it in 46 quarters since. The position peaked at $96M in Q3 2025. 1,090 funds tracked by Wall St. Rank hold XYL as of Q2 2026.

  • David Shaw held 600,585 shares of Xylem worth $71M as of Q2 2026.
  • David Shaw sold 41,477 Xylem shares in Q2 2026, an estimated $4.79M.
  • Xylem made up 0.03% of David Shaw's portfolio in Q2 2026, its #587 holding.
  • David Shaw first reported a position in Xylem in Q2 2013 and has held it in 46 quarters since.
  • David Shaw's Xylem position peaked at $96M in Q3 2025.
  • 1,090 funds tracked by Wall St. Rank held Xylem as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.